| Name | Title | Contact Details |
|---|---|---|
Chad Morin |
Senior Vice President, Chief Compliance Officer | Profile |
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
VLST is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MethylGene Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Glow Skin Care Studio is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.